Vyriad VV169 In Vivo CAR T Enters Phase 1 at Mayo Clinic

Q: What is VV169 and how does it differ from approved CAR T therapies?

VV169 is an in vivo CAR T therapy that delivers an anti-BCMA CAR gene directly to a patient's T cells via an IV-infused, targeted lentiviral vector. Unlike approved ex vivo products such as ide-cel or cilta-cel, VV169 does not require removing patient cells, manufacturing CAR T cells outside the body over several weeks, and reinfusing them. The entire process occurs inside the patient.

Q: What is blinded and retargeted VSV-G pseudotyping?

VSV-G is a viral envelope glycoprotein commonly used in lentiviral vectors, but it naturally infects a wide range of cell types. Vyriad's platform "blinds" the native broad tropism and replaces it with a T cell-specific targeting ligand, allowing the vector to selectively transduce T cells when administered systemically.

Q: Why is BCMA targeted in multiple myeloma?

BCMA (B-cell maturation antigen) is highly expressed on malignant plasma cells in multiple myeloma and has low expression on most normal tissues, making it a tractable target for CAR T and bispecific antibody therapies. Multiple approved and investigational therapies target BCMA in this disease.

Q: What are the primary risks Vyriad's Phase 1 trial needs to address?

Lentiviral vectors integrate into the host genome, which carries a theoretical risk of insertional mutagenesis — disruption of tumor suppressor genes or activation of oncogenes near the integration site. The Phase 1 safety assessment will evaluate this alongside infusion-related toxicities and cytokine release syndrome signals typical of BCMA-targeted CAR T approaches.

Q: How does in vivo CAR T affect the broader cell therapy manufacturing industry?

If in vivo CAR T approaches prove clinically viable, they would substantially reduce demand for the complex, personalized ex vivo manufacturing infrastructure — leukapheresis, GMP clean rooms, patient-specific lot release — that currently underpins the cell therapy [CDMO](https://synbiointel.com/glossary/cdmo) sector. Commercial-scale in vivo products would instead resemble traditional biologics manufacturing: batch-produced, shelf-stable, and distributable through standard oncology pharmacy channels.


## Does Vyriad's VV169 Make Ex Vivo CAR T Manufacturing Obsolete for Myeloma?

**Up to 40 relapsed/refractory multiple myeloma patients** will be enrolled in Vyriad's Phase 1 trial of VV169, an off-the-shelf, in vivo [CAR-T](https://synbiointel.com/glossary/car-t) therapy that generates CAR T cells directly inside the patient's body — no leukapheresis, no weeks-long manufacturing wait. The FDA cleared Vyriad's IND application, and the trial is now actively enrolling at Mayo Clinic under principal investigator Yi Lin, M.D., Ph.D., head of Mayo's in vivo CAR T program.

VV169 targets BCMA (B-cell maturation antigen), the same antigen addressed by approved ex vivo products such as ide-cel and cilta-cel. The critical differentiator is delivery mechanism: Vyriad uses a targeted lentiviral vector built on blinded and retargeted VSV-G pseudotyping. When administered intravenously, the vector homes specifically to T cells, transduces them in situ, and drives expression of an anti-BCMA CAR payload — bypassing the logistics chain that makes conventional [cell therapy](https://synbiointel.com/glossary/cell-therapy) inaccessible to many patients. The trial's primary endpoints are safety, dose-limiting toxicities, and recommended Phase 2 dose. Secondary endpoints include preliminary efficacy signals and in vivo CAR T cell expansion and persistence. The trial identifier is NCT07802717.

---

## The Technology: VSV-G Retargeting as a Systemic Delivery Engine

Vyriad's platform centers on what the company calls "blinded and retargeted VSV-G pseudotyping." Native VSV-G has broad tropism — it will transduce almost any cell it encounters, which is precisely the problem for systemic delivery. Vyriad's approach ablates that promiscuous binding and replaces it with a T cell-specific ligand, restricting transduction to the intended compartment.

This is technically distinct from other in vivo CAR T approaches in development that rely on lipid nanoparticles (LNPs) or adeno-associated viral vectors. Lentiviral vectors integrate stably into the host genome, which supports durable CAR expression — relevant for persistence data that the trial's secondary endpoints will capture. The tradeoff, as with any integrating vector, is insertional mutagenesis risk, which the Phase 1 safety assessment will need to address rigorously.

The company is privately held and based in Rochester, Minnesota — notably co-located with Mayo Clinic, the trial site. Stephen Russell, M.D., Ph.D., serves as Chief Scientific Officer; his quote in the release explicitly frames the problem VV169 is designed to solve: "waiting weeks for a therapy to be manufactured can be a significant barrier." That framing is commercially pointed — it directly targets the operational bottleneck that limits market penetration for approved ex vivo CAR T products.

---

## Why This Trial Matters Beyond Vyriad

The BCMA-targeted myeloma space is already crowded at the ex vivo level. What the field lacks is a validated in vivo delivery route that achieves comparable response rates without the manufacturing infrastructure. Several groups — including [ArsenalBio](https://synbiointel.com/companies/arsenalbio) and academic programs — are pursuing in vivo CAR T via LNP-mRNA formats. Vyriad's lentiviral approach competes on a different axis: stable integration versus transient expression.

**The skeptical read:** Phase 1 trials in relapsed/refractory myeloma are notoriously difficult to interpret. Patients in this population have typically received multiple prior lines, including proteasome inhibitors, IMiDs, and increasingly prior BCMA-targeted therapies. If VV169's eventual efficacy data is generated against a heavily pre-treated cohort that includes prior BCMA exposure, response rates will face a high bar. The trial's eligibility criteria will determine how cleanly those data can be positioned against ex vivo benchmarks.

**The structural advantage:** If VV169 shows even modest efficacy with a manageable safety profile, the access argument becomes commercially decisive. Ex vivo CAR T requires specialized apheresis centers, weeks of slot scheduling at certified treatment sites, and bridging therapy during manufacturing. An IV-infused, off-the-shelf product — if it works — compresses that to a single clinic visit. That matters enormously in community oncology settings outside major academic centers.

**Industry trajectory:** In vivo gene delivery for [cell therapy](https://synbiointel.com/glossary/cell-therapy) reprogramming is where significant R&D capital is flowing. Vyriad's IND clearance and active enrollment represent one of the more advanced clinical datapoints for a lentiviral-based in vivo CAR T approach. The 40-patient enrollment cap gives the trial sufficient size to generate preliminary expansion and persistence pharmacodynamics — data the field urgently needs to evaluate whether in vivo-generated CAR T cells behave comparably to their ex vivo counterparts in terms of functional fitness and durability.

Results from this trial will be closely watched by platform developers, oncology CDMOs currently dependent on ex vivo manufacturing revenues, and payers modeling long-term cost-of-goods trajectories for [cell therapy](https://synbiointel.com/glossary/cell-therapy) at scale.

---

## Key Takeaways

- **Vyriad's VV169** is an in vivo, off-the-shelf anti-BCMA [CAR-T](https://synbiointel.com/glossary/car-t) therapy; it generates CAR T cells directly inside the patient via IV infusion.
- **The Phase 1 trial** enrolls up to 40 relapsed/refractory multiple myeloma patients at Mayo Clinic (NCT07802717), led by Yi Lin, M.D., Ph.D.
- **The platform** uses blinded and retargeted VSV-G pseudotyped lentiviral vectors — a stable-integrating approach distinct from LNP-mRNA competitors.
- **Primary endpoints** are safety, dose-limiting toxicities, and recommended Phase 2 dose; secondary endpoints include efficacy signals and CAR T cell expansion/persistence in vivo.
- **The commercial thesis** rests on eliminating ex vivo manufacturing delays — a bottleneck that caps market access for approved myeloma CAR T products.
- **Key risk:** Lentiviral insertional mutagenesis safety signal and efficacy comparability against ex vivo benchmarks remain to be established in the clinic.

---

## Frequently Asked Questions

**What is VV169 and how does it differ from approved CAR T therapies?**
VV169 is an in vivo CAR T therapy that delivers an anti-BCMA CAR gene directly to a patient's T cells via an IV-infused, targeted lentiviral vector. Unlike approved ex vivo products such as ide-cel or cilta-cel, VV169 does not require removing patient cells, manufacturing CAR T cells outside the body over several weeks, and reinfusing them. The entire process occurs inside the patient.

**What is blinded and retargeted VSV-G pseudotyping?**
VSV-G is a viral envelope glycoprotein commonly used in lentiviral vectors, but it naturally infects a wide range of cell types. Vyriad's platform "blinds" the native broad tropism and replaces it with a T cell-specific targeting ligand, allowing the vector to selectively transduce T cells when administered systemically.

**Why is BCMA targeted in multiple myeloma?**
BCMA (B-cell maturation antigen) is highly expressed on malignant plasma cells in multiple myeloma and has low expression on most normal tissues, making it a tractable target for CAR T and bispecific antibody therapies. Multiple approved and investigational therapies target BCMA in this disease.

**What are the primary risks Vyriad's Phase 1 trial needs to address?**
Lentiviral vectors integrate into the host genome, which carries a theoretical risk of insertional mutagenesis — disruption of tumor suppressor genes or activation of oncogenes near the integration site. The Phase 1 safety assessment will evaluate this alongside infusion-related toxicities and cytokine release syndrome signals typical of BCMA-targeted CAR T approaches.

**How does in vivo CAR T affect the broader cell therapy manufacturing industry?**
If in vivo CAR T approaches prove clinically viable, they would substantially reduce demand for the complex, personalized ex vivo manufacturing infrastructure — leukapheresis, GMP clean rooms, patient-specific lot release — that currently underpins the cell therapy [CDMO](https://synbiointel.com/glossary/cdmo) sector. Commercial-scale in vivo products would instead resemble traditional biologics manufacturing: batch-produced, shelf-stable, and distributable through standard oncology pharmacy channels.